{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:50Z","timestamp":1791489650477,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":239,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472062"],"award-info":[{"award-number":["82472062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171955"],"award-info":[{"award-number":["82171955"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272088"],"award-info":[{"award-number":["82272088"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102034"],"award-info":[{"award-number":["82102034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2021B0101420006"],"award-info":[{"award-number":["2021B0101420006"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011672"],"award-info":[{"award-number":["2024A1515011672"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101416","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:26:35Z","timestamp":1788963995000},"page":"101416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distinct clinic and ultrasound imaging manifestations associated with HER2-low expression in triple-negative breast cancer"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8141-1286","authenticated-orcid":false,"given":"Maohua","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101416_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/nrclinonc.2013.230","article-title":"Breast cancer: updated guideline recommendations for HER2 testing","volume":"11","author":"Rakha","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0002","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0004","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101416_bib0005","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101416_bib0006","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S1470-2045(19)30158-5","article-title":"Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers","volume":"20","author":"Pusztai","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101416_bib0008","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0009","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0010","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1001\/jamaoncol.2022.4175","article-title":"An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-Low)","volume":"8","author":"Prat","year":"2022","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0011","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41416-023-02403-x","article-title":"Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases","volume":"129","author":"Zhu","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101416_bib0012","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41467-023-40715-x","article-title":"Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer","volume":"14","author":"Dai","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101416_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-024-07317-7","article-title":"Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"206","author":"Shi","year":"2024","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101416_bib0014","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13058-024-01783-z","article-title":"HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: are they connected?","volume":"26","author":"Baez-Navarro","year":"2024","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113371","article-title":"Characterisation of luminal and triple-negative breast cancer with HER2 low protein expression","volume":"195","author":"Atallah","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101416_bib0016","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222646","article-title":"Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers","volume":"308","author":"Ramtohul","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.ctarc.2026.101416_bib0017","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","article-title":"Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics","volume":"34","author":"Zheng","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0018","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00330-023-09990-6","article-title":"Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer","volume":"34","author":"Guo","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0019","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jnci\/djab121","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101416_bib0020","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0021","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101416_bib0022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101416_bib0023","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0024","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: neoSTEEP","volume":"41","author":"Litton","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0025","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(11)70378-3","article-title":"A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints","volume":"13","author":"Fumagalli","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0026","article-title":"ACR BI-RADS\u00ae Atlas","author":"D'Orsi","year":"2013","journal-title":"Breast Imag. Report. Data Syst."},{"key":"10.1016\/j.ctarc.2026.101416_bib0027","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.ctarc.2026.101416_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/096228029900800102","article-title":"Multiple imputation: a primer","volume":"8","author":"Schafer","year":"1999","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0029","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0030","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.4143\/crt.2022.1633","article-title":"Prognostic value of the evolution of HER2-low expression after Neoadjuvant chemotherapy","volume":"55","author":"Ma","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101416_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ. Breast. Cancer"},{"key":"10.1016\/j.ctarc.2026.101416_bib0032","article-title":"Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-low and HER2-0 breast cancer","volume":"9","author":"Schettini","year":"2024","journal-title":"ESMo Open."},{"key":"10.1016\/j.ctarc.2026.101416_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102538","article-title":"Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis","volume":"115","author":"Ergun","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2026.101416_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156669","article-title":"The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis","volume":"15","author":"Tang","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0035","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0036","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101416_bib0037","first-page":"3571","article-title":"Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study","volume":"13","author":"Li","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0038","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC. Med."},{"key":"10.1016\/j.ctarc.2026.101416_bib0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13058-023-01639-y","article-title":"Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low","volume":"25","author":"Hu","year":"2023","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0040","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.2147\/CMAR.S276422","article-title":"Associations of estrogen receptor, progesterone receptor, Human epidemic growth factor receptor-2 and ki-67 with ultrasound signs and prognosis of breast cancer patients","volume":"Volume 13","author":"Zhao","year":"2021","journal-title":"Cancer Manage Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0041","article-title":"Association between vascular index measured via Superb microvascular imaging and molecular subtype of breast cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0042","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1016\/j.acra.2024.01.023","article-title":"The emergence of the potential therapeutic targets: ultrasound-based radiomics in the prediction of Human epidermal growth factor receptor 2-low breast cancer","volume":"31","author":"Du","year":"2024","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.ctarc.2026.101416_bib0043","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ctarc.2026.101416_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-022-01516-0","article-title":"Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment","volume":"24","author":"Wang","year":"2022","journal-title":"Breast. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101416_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41591-022-02155-w","article-title":"Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"29","author":"Ogier du Terrail","year":"2023","journal-title":"Nat. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:43:07Z","timestamp":1791488587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":45,"alternative-id":["S2468294226003266"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101416","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct clinic and ultrasound imaging manifestations associated with HER2-low expression in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101416"}}